Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Uyo, Uyo, 520271, Akwa Ibom State, Nigeria.
Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, 410001, Enugu State, Nigeria.
Sci Rep. 2023 Dec 18;13(1):22536. doi: 10.1038/s41598-023-49322-8.
Assessing the health-related quality of life (HRQoL) of people with diabetes is important to evaluate treatment effectiveness and identify interventions that would be beneficial to the patients. This descriptive cross-sectional study aimed to assess the HRQoL of people with diabetes visiting 15 community pharmacies in Akwa Ibom State, Nigeria, and to identify its determinants. The English (Nigeria) version of the EQ-5D-5L was administered to 420 eligible patients between August and September 2021. Data were analyzed with SPSS (IBM version 25.0) and presented descriptively; differences in HRQoL scores were examined using inferential statistics. Statistical significance was set at p < 0.05. Most participants (56.8%) were female; 193 (49.6%) were between the ages of 30 and 49. The median (interquartile range, IQR) for the EQ VAS and EQ-5D-5L index scores, respectively, were 80.0 (65.0-85.0) and 0.77 (0.62-0.90). Most participants reported problems with usual activities (52.7%), pain/discomfort (60.2%), and anxiety/depression (57.6%). The EQ VAS score and EQ-5D-5L utility index were significantly (p < 0.05) associated with respondents' age, marital status, work status, and personal monthly income. The HRQoL of participants was relatively high. Nevertheless, implementing strategies aimed at pain management and providing psychological support for people with diabetes in Nigeria may improve their HRQoL.
评估糖尿病患者的健康相关生活质量(HRQoL)对于评估治疗效果和确定对患者有益的干预措施非常重要。本描述性横断面研究旨在评估在尼日利亚阿克瓦伊博姆州的 15 家社区药店就诊的糖尿病患者的 HRQoL,并确定其决定因素。2021 年 8 月至 9 月期间,对 420 名符合条件的患者使用英语(尼日利亚)版 EQ-5D-5L 进行了评估。使用 SPSS(IBM 版本 25.0)对数据进行了分析,并进行了描述性分析;使用推断统计学检查了 HRQoL 评分的差异。统计显著性设置为 p < 0.05。大多数参与者(56.8%)为女性;193 名(49.6%)年龄在 30 岁至 49 岁之间。EQ VAS 和 EQ-5D-5L 指数评分的中位数(四分位距,IQR)分别为 80.0(65.0-85.0)和 0.77(0.62-0.90)。大多数参与者报告在日常生活活动(52.7%)、疼痛/不适(60.2%)和焦虑/抑郁(57.6%)方面存在问题。EQ VAS 评分和 EQ-5D-5L 效用指数与受访者的年龄、婚姻状况、工作状况和个人月收入显著相关(p < 0.05)。参与者的 HRQoL 相对较高。然而,在尼日利亚实施旨在管理疼痛和为糖尿病患者提供心理支持的策略可能会提高他们的 HRQoL。